How to Check If Ozempic Is Real: What the Pen in Your Hand Can Prove

If you are holding a semaglutide pen you are not certain about, the uncomfortable answer is that nothing visible on it settles the question. Testing reported by Germany's regulator, carried out by the manufacturer on apparently relabelled Ozempic pens in German presentation, found insulin inside them instead of semaglutide. That is the plainest demonstration available that a convincing device can hold an entirely different medicine.

What a careful inspection can still do is catch the crude copies, preserve evidence while it exists, and tell you when to stop.

Key Takeaways:

• A pen that passes every visual test has demonstrated competent packaging, not authentic contents. The German falsifications were identified by laboratory analysis, not by inspection.
• Ozempic has been CDSCO-approved and marketed in India since December 2025. An Ozempic-labelled Indian pen is not automatically an informal import.
• "It looks nothing like the pictures online" is not a finding. Indian generic semaglutide pens launched from March 2026 in their own devices and need not resemble Ozempic.
• Provenance and authenticity are two separate enquiries. A dispensing record sits outside the pack, where a falsifier's work does not reach.
• A pen under suspicion is worth more as evidence than as medicine. Set it aside, photograph it, and report it before injecting.

The German finding is worth sitting with, because it inverts the usual assumption about falsified medicine. The fear is normally that a fake contains nothing and will do nothing. Here the pens had apparently been relabelled and the cartridges held a different active medicine altogether. The German regulator describes the falsifications as posing a considerable health hazard, which is a different category of problem from a wasted purchase.

That case remained under investigation when the alert was published. No amount of handling, dialling or squinting at print would have surfaced it, because the one variable that mattered sat inside a sealed cartridge that no inspection opens.

The same lesson arrives from the opposite direction in regulatory records. WHO's alert correction documents a falsified pack carrying a batch number that was itself genuine. Falsifiers copy cartons, batch numbers and serials, because those are the surfaces they control.

A pen that survives every visual test has demonstrated competent packaging and nothing beyond it. That is still worth knowing, since cheap copies fail these tests and the reader who runs them stops earlier than one who does not.

This is where a lot of advice written before 2026 now misleads. CDSCO records describe Ozempic as an approved semaglutide pre-filled pen, launched in India on 12 December 2025. A further brand sourced from it followed in February 2026, and several Indian semaglutide generic injections arrived from 20 and 21 March 2026.

An Ozempic-labelled pen in India is therefore not automatically a smuggled or informally imported one. The reverse also holds: an Indian generic pen is under no obligation to resemble Ozempic, so "it looks nothing like the pictures online" is not a finding.

Provenance and authenticity are two separate enquiries, and of the two the paperwork question is by some distance the more tractable.

Work through this in order, and compare against the same Indian presentation the pen claims to be rather than foreign web photographs.

• Set the pen aside unused: A pen under suspicion is worth more as evidence than as medicine, and injecting it forecloses every option below.
• Photograph the carton, label, closure, identifiers and any code before handling the pen further, then retain the carton, the pen, the needles and the purchase record together.
• Check that the carton and the pen agree with each other: Product name, strength, batch number and expiry date should match across both. Printing should be sharp and labels should lie flat. A mismatch between carton and pen, poor label application or a disturbed closure points strongly to tampering. Agreement across all of them establishes only that the packaging was competently produced.
• Watch the body as the dial is turned: On the German- and US-market pens these cases were documented against, an authentic Ozempic pen does not lengthen as the dial turns, and the clear medicine-viewing window carries no graduated scale. No Indian pen specification was located, so treat this as a cue rather than an Indian standard. A protruding scale or dial has been documented in falsified pens.
• Look at the liquid: Approved labels describe the solution as clear and colourless. Cloudiness, colour or visible particles mean the pen should not be used. Clear liquid establishes nothing about identity, concentration, sterility or how the pen was stored.
• Treat cross-market warnings as reference, not Indian specification: US manufacturer material describes a carton perforation and states that the dose window should display only doses intended for that pen. A US manufacturer statement on a 2023 counterfeit in that market records mismatched needle branding, a carton lot number printed on the needle tab, and a blue-tinted inner cover where the genuine one is transparent. No equivalent Indian specification was located, and needle details and counts vary by market.
• Do not read a successful scan as confirmation: No primary source documents a consumer-verifiable code on the Indian pack, and a code that opens a plausible website has proved only that the link resolves. Copied codes scan successfully.

Being specific about the gap matters more than filling it. As of 2026, no India-specific authentication sheet, carton-finish specification, tamper-seal drawing, code destination, consumer serial-verification portal, needle specification or authoritative image set for Indian Ozempic could be located in primary sources. The exact positions on the Indian carton where batch, serial and expiry are printed are unverified.

There is no Indian route by which a reader can self-certify a pen, and any resource presenting itself as one should be treated with scepticism.

Three routes exist and they are not substitutes for one another.

The manufacturer can check its own records and inspect the article. Novo Nordisk India can be reached at [email protected] or on +91 80 4030 3200, using contact details taken from the company's own Indian website rather than from the pack or the person who supplied it. Send the photographs and the identifiers, and expect that a suspected falsification may require the physical sample. The company's falsified medicines position sets out how it handles these reports.

A manufacturer's confirmation tests records and inspects packaging. It is valuable and is still not laboratory proof of what a cartridge contains.

The regulator handles it as a drug-quality complaint: a different filing with a different purpose that puts the article into the enforcement system rather than into one company's records. CDSCO can be contacted at [email protected] or [email protected], or on 1800 11 1454.

A reaction is a separate report and goes to a different body. The Pharmacovigilance Programme of India takes adverse-event reports on 1800 180 3024, through its consumer form and app, or at an ADR Monitoring Centre. Filing one does not file a quality complaint, and filing a quality complaint does not record a reaction. Anyone who has already injected a suspect pen and felt unwell needs both, and needs a doctor first.

None of this answers the question underneath the one you came with, which is whether this class of medicine is appropriate for you at all. That is a clinical judgement for a registered medical practitioner, and in India it is also a question of who may lawfully prescribe it.

Not certain about a semaglutide pen or whether this medicine is right for you? Speak to a Voy clinician before a needle goes anywhere.

This article is for general information and education only and is not medical advice, diagnosis, or treatment. GLP-1 and other medications referenced are prescription-only and are appropriate only for certain people under the supervision of a qualified clinician. Do not start, stop, or change any medication based on this article. Please consult a registered medical practitioner about your individual circumstances. Information reflects what was available at the time of review and may change.